@article{db0ba53126a043779f9d15fc51e0609e,
title = "Better functional capacity and cognitive performance in clozapine responders compared to non-responders: A cross-sectional study",
keywords = "Cognitive functioning, Functional capacity, Schizophrenia, Treatment resistant schizophrenia, Ultra-treatment resistant schizophrenia",
author = "Nucifora, {Frederick C.} and Baker, {Krista K.} and Ashley Stricklin and Arlene Cuerdo and Parke, {Kathryn R.} and Samantha DuBois and Nucifora, {Leslie G.} and Margolis, {Russell L.} and Akira Sawa and Harvey, {Philip D.}",
note = "Funding Information: In the last year, Dr. Harvey has received consulting fees or travel reimbursements from Alkermes, Bio Excel, Boehringer Ingelheim, Intra-Cellular Therapies, Minerva Pharma, Otsuka America, Regeneron, Roche Pharma, and Sunovion Pharma. He receives royalties from the Brief Assessment of Cognition in Schizophrenia and the MATRICS Consensus Battery. He has a research grant from Takeda and from the Stanley Medical Research Foundation. He is chief scientific officer of iFunction, the owner of the assessment software. All other authors have nothing to declare. ",
year = "2021",
month = mar,
doi = "10.1016/j.schres.2020.11.018",
language = "English (US)",
volume = "229",
pages = "134--136",
journal = "Schizophrenia Research",
issn = "0920-9964",
publisher = "Elsevier",
}